Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy

M.P. Steenbeek, M.H.D. van Bommel*, M.G. Harmsen, N. Hoogerbrugge, H.C. van Doorn, J.H.M. Keurentjes, M. van Beurden, R.P. Zweemer, K.N. Gaarenstroom, C.G.J. Penders, M.M.A. Brood-van Zanten, M.C. Vos, J.M. Piek, L.R.C.W. van Lonkhuijzen, M.J.A. Apperloo, S.F.P.J. Coppus, J. IntHout, J.A. de Hullu, R.P.M.G. Hermens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Objective. Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the age of 40 years to reduce ovarian cancer risk. In the TUBA-study, a multicenter preference study (NCT02321228), BRCA1/2-PV carriers are offered a choice: the standard strategy of risk-reducing salpingo-oophorectomy or the novel strategy of risk-reducing salpingectomy with delayed oophorectomy. We evaluated feasibility and effectiveness of a patient decision aid for this choice. Methods. Premenopausal BRCA1/2-PV carriers were counselled for risk-reducing surgical options in the TUBA study; the first cohort was counselled without and the second cohort with decision aid. Evaluation was performed using digital questionnaires for participating women and their healthcare professionals. Outcome measures included actual choice, feasibility (usage and experiences) and effectiveness (knowledge, cancer worry, decisional conflict, decisional regret and self-estimated influence on decision). Results. 283 women were counselled without and 282 women with decision aid. The novel strategy was chosen less frequently in women without compared with women with decision aid (67% vs 78%, p = 0.004). The decision aid was graded with an 8 out of 10 by both women and professionals, and 78% of the women would rec-ommend this decision aid to others. Users of the decision aid reported increased knowledge about the options and increased insight in personal values. Knowledge on cancer risk, decisional conflict, decisional regret and can-cer worry were similar in both cohorts. Conclusions. The use of the patient decision aid for risk-reducing surgery is feasible, effective and highly ap-preciated among BRCA1/2-PV carriers facing the decision between salpingo-oophorectomy or salpingectomy with delayed oophorectomy. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
Original languageEnglish
Pages (from-to)371-377
Number of pages7
JournalGynecologic Oncology
Issue number2
Publication statusPublished - 1 Nov 2021


  • Decision aid
  • BRCA
  • Ovarian cancer
  • Risk-reducing salpingo-oophorectomy
  • Salpingectomy


Dive into the research topics of 'Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy'. Together they form a unique fingerprint.

Cite this